...ip arrays have been developed for affinity capture... ProteinChip chemical surfaces allow differential ...hemical properties. Each chip has eight different ...d the chips are color-coded with a unique hydropho...
Thermal Printer, 120 V from Bio-Rad
...Assay with FAM-Labeled Substrate (green fluorescen...e serine protease activation • No lysing, fix...its utilize cell-permeable, fluorescently labeled ... chymotrypsin-like activity in whole living cells....
...ay systems, known as ChemiArrayTM Mouse Cytokine A...ith current methodologies. Besides the ability to ...nt a more accurate reflection of active cytokine l... and no amplification step is needed. Furthermore,...
Biology Products:(Date:11/24/2009)...nt bank KTA Capital,s client Neuren Pharmaceutical...le note private placement with a U.S. institutiona...KTA Capital as Neuren,s exclusive placement agent ...PRWEB) November 23, 2009 -- The independent New Yo...ital") has announced that its client Neuren P...
(Date:11/24/2009)...irstCall/ -- Sigma-Aldrich Corporation (Nasdaq: S...nce on Tuesday, December 1st at 1:45 PM GMT in Lon... via live audio broadcast over the Internet availa...com/ . Users can click the "Webcast" icon to acc...gma-Aldrich is a leading Life Science and High Tec...
(Date:11/24/2009)...ewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NG...oping and commercializing novel pain management th...sident and Chief Executive Officer, is scheduled t...Care Conference, to be held December 1-2, 2009 at ...,, Mr. DiTonno and Stephen Ghiglieri, Chief Fin...
(Date:11/24/2009)... been met for patients with advanced-stage, or ...Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on endoc...e efficacy data from a Phase 2 study with its targ...ly AN-152), in patients with advanced or recurrent...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4